Prospects and challenges of applying chimeic antigen receptor cell therapy in autoimmune diseases

doi:10.16138/j.1673-6087.2024.06.02

Abstract

Abstract:

In recent years, chimeric antigen receptor (CAR) cell therapy, as an emerging immunotherapy method, has achieved significant results in the field of hematological cancer treatment. However, applying CAR cell therapy to autoimmune diseases remains a relatively novel and challenging method. Autoimmune diseases are caused by an individual’s immune system mistakenly attacking their own tissues, and their complex etiology and diverse symptoms make traditional treatment methods and biologics still unable to meet clinical needs. CAR cell therapy, using engineering T cells or other immune cells to recognize and kill specific antigens, is highly targeted and durable, which providing new hope for the treatment of autoimmune diseases. This article systematically reviews the latest research progress and challenges of using CAR cell therapy in the treatment of autoimmune diseases, such as safety, immune response issues, and difficulties in clinical application.

Key words: Chimeric antigen receptor, Cell therapy, Autoimmune diseases, Safety, Clinical application

CLC Number:

R593.2

GAO Jie. Prospects and challenges of applying chimeic antigen receptor cell therapy in autoimmune diseases[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(06): 363-366.

References 22

[1]	Conrad N, Misra S, Verbakel JY, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK[J]. Lancet, 2023, 401(10391): 1878-1890.
[2]	Danieli MG, Casciaro M, Paladini A, et al. Exposome: epigenetics and autoimmune diseases[J]. Autoimmun Rev, 2024, 23(6): 103584.
[3]	Ramírez-Valle F, Maranville JC, Roy S, et al. Sequential immunotherapy: towards cures for autoimmunity[J]. Nat Rev Drug Discov, 2024, 23(7): 501-524. doi: 10.1038/s41573-024-00959-8 pmid: 38839912
[4]	Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases[J]. Lancet, 2023, 402(10416): 2034-2044. doi: 10.1016/S0140-6736(23)01126-1 pmid: 37748491
[5]	Maalej KM, Merhi M, Inchakalody VP, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances[J]. Mol Cancer, 2023, 22(1): 20. doi: 10.1186/s12943-023-01723-z pmid: 36717905
[6]	Zhou D, Zhu X, Xiao Y. CAR-T cell combination therapies in hematologic malignancies[J]. Exp Hematol Oncol, 2024, 13(1): 69. doi: 10.1186/s40164-024-00536-0 pmid: 39026380
[7]	叶柏新, 胡永仙, 张明明, 等. 脂质纳米粒-mRNA递送系统及其在嵌合抗原受体T细胞治疗中的应用[J]. 浙江大学学报(医学版), 2022, 51(2): 185-191.
[8]	Wu Z, Wang Y, Jin X, et al. Universal CAR cell therapy: challenges and expanding applications[J]. Transl Oncol, 2024, 14(51): 102147.
[9]	Li YR, Lyu Z, Chen Y, et al. Frontiers in CAR-T cell therapy for autoimmune diseases[J]. Trends Pharmacol Sci, 2024, 45(9): 839-857.
[10]	Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-Cell therapy in autoimmune disease - a case series with follow-up[J]. N Engl J Med, 2024, 390(8): 687-700.
[11]	Wang W, He S, Zhang W, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial[J]. Ann Rheum Dis, 2024, 83(10): 1304-1314.
[12]	Pecher AC, Hensen L, Klein R, et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome[J]. JAMA, 2023, 329(24): 2154-2162.
[13]	Sheng L, Zhang Y, Song Q, et al. Concurrent remission of lymphoma and Sjögren’s disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma[J]. Front Immunol, 2023, 14: 1298815.
[14]	Haghikia A, Hegelmaier T, Wolleschak D, et al. Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis[J]. Ann Rheum Dis, 2024, 83(11): 1597-1598.
[15]	Wang X, Wu X, Tan B, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis[J]. Cell, 2024, 187(18): 4890-4904.
[16]	Li W, Feng J, Peng J, et al. Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: a bibliometric analysis from 2004 to 2023[J]. Hum Vaccin Immunother, 2024, 20(1): 2415187.
[17]	于奕奕, 胡佳琪, 靳正逸, 等. 通用型CAR-NK细胞治疗系统性红斑狼疮的应用与展望[J]. 海军军医大学学报, 2024, 45(10):1199-1204.
[18]	Elsallab M, Ellithi M, Lunning MA, et al. Second primary malignancies after commercial CAR T-cell therapy[J]. Blood, 2024, 143(20): 2099-2105.
[19]	Kochenderfer JN, Somerville RPT, Lu T, et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy[J]. Mol Ther, 2017, 25(10): 2245-2253. doi: S1525-0016(17)30318-0 pmid: 28803861
[20]	Lei T, Wang Y, Zhang Y, et al. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy[J]. Leukemia, 2024, 38(12):2517-2543.
[21]	Hosseinkhani N, Derakhshani A, Kooshkaki O, et al. Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies?[J]. Int J Mol Sci, 2020, 21(21): 8305.
[22]	Liu Q, Li J, Zheng H, et al. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T[J]. Mol Cancer, 2023, 22(1): 28. doi: 10.1186/s12943-023-01735-9 pmid: 36750830